Nautilus Biotechnology, Inc. — Director's Dealing 2021

Jun 11, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Nautilus Biotechnology, Inc. (NAUT)
CIK: 0001808805
Period of Report: 2021-05-24

Reporting Person: PERCEPTIVE ADVISORS LLC (Former Director)
Reporting Person: PERCEPTIVE LIFE SCIENCES MASTER FUND LTD (Former Director)
Reporting Person: EDELMAN JOSEPH (Former Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-05-24	Common Stock	P	7063	$10.05	Acquired	497038	Direct
2021-06-09	Common Stock	P	5500000	$10	Acquired	5997038	Indirect
2021-06-09	Common Stock	J	2914113	—	Acquired	8911151	Indirect

Footnotes

F1: The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager of Master Fund. Joseph Edelman is the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.

F2: Acquired pursuant to the business combination by and among ARYA Sciences Acquisition Corp III, Mako Merger Sub, Inc. and Nautilus Biotechnology, Inc. ("Old Nautilus") in exchange for shares of Old Nautilus previously held by the Master Fund.